Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
OSR Holdings ( (OSRH) ) just unveiled an update.
On March 27, 2026, OSR Holdings, Inc. and its subsidiary Vaximm AG entered into a new binding term sheet with BCM Europe AG for a revised global exclusive license of the drug candidate VXM01, replacing a prior 2025 agreement. Under the revised structure, OSR Holdings becomes a direct counterparty and primary recipient of up to $815 million in milestone and royalty payments, while also committing to provide Vaximm with up to $30 million in development financing, with the deal still contingent on due diligence and customary approvals.
The arrangement strengthens OSR Holdings’ financial stake and central role in the commercialization pathway for VXM01, potentially enhancing its long-term revenue visibility and influence over the asset’s global development strategy. For stakeholders, the shift consolidates value capture at the parent-company level and underscores BCME’s continued commitment to advancing VXM01, though final economics remain subject to execution of definitive agreements and satisfaction of closing conditions.
More about OSR Holdings
OSR Holdings, Inc., through its wholly owned subsidiary Vaximm AG, operates in the biopharmaceutical sector with a focus on developing and commercializing VXM01. The company’s structure positions OSR Holdings as the primary financial beneficiary of licensing arrangements, while Vaximm provides the development platform for its therapeutic assets.
Average Trading Volume: 1,589,565
Technical Sentiment Signal: Sell
Current Market Cap: $19.43M
For an in-depth examination of OSRH stock, go to TipRanks’ Overview page.